Researchers at Northwestern and George Washington (GW) universities have developed the first-ever transient pacemaker, a wireless, battery-free, fully implantable pacing device that disappears after its no longer needed.
The thin, flexible, lightweight device could be used in patients who need temporary pacing after cardiac surgery or while waiting for a permanent pacemaker. All components of the pacemaker are biocompatible and naturally absorb into the bodys biofluids over the course of five to seven weeks without needing surgical extraction.
The device wirelessly harvests energy from an external, remote antenna using near-field communication protocols the same technology used in smartphones for electronic payments and in RFID tags. This eliminates the need for bulky batteries and rigid hardware, including wires (or leads). This can lead to infections, but they can also become enveloped in scar tissue, causing further damage when removed.
The study will be published on 28th June in the journal Nature Biotechnology. The paper demonstrates the devices efficacy across a series of large and small animal models.
Hardware placed in or near the heart creates risks for infection and other complications, said Northwesterns John A. Rogers, who led the devices development. Our wireless, transient pacemakers overcome key disadvantages of traditional temporary devices by eliminating the need for percutaneous leads for surgical extraction procedures, thereby offering the potential for reduced costs and improved outcomes in patient care. This unusual type of device could represent the future of temporary pacing technology.
Sometimes patients only need pacemakers temporarily, perhaps after an open-heart surgery, heart attack or drug overdose, said Dr. Rishi Arora, a cardiologist at Northwestern Medicine who co-led the study. After the patients heart is stabilized, we can remove the pacemaker. The current standard of care involves inserting a wire, which stays in place for three to seven days. These have potential to become infected or dislodged.
The transient electronics platform opens an entirely new chapter in medicine and biomedical research, said GWs Igor Efimov, who co-led the study with Rogers and Arora. The bioresorbable materials at the foundation of this technology make it possible to create a whole host of diagnostic and therapeutic transient devices for monitoring progression of diseases and therapies, delivering electrical, pharmacological, cell therapies, gene reprogramming and more.
Currently, to set up temporary pacing after open-heart surgery, surgeons must sew on temporary pacemaker electrodes on the heart muscle during surgery. These have leads that exit the front of a patients chest, connecting to an external pacing box that delivers a current to control the hearts rhythm.
When the temporary pacemaker is no longer needed, physicians remove the pacemaker electrodes. Although uncommon, potential complications of implanted temporary pacemakers include infection, dislodgement, torn or damaged tissues, bleeding, and blood clots.
With Northwestern and GWs transient pacemaker, surgeons and patients can sidestep this potentially risky procedure. The fully implantable device is light, 250 microns thick, and weighing less than half a gram. Soft and flexible, it encapsulates electrodes that softly laminate onto the hearts surface to deliver an electrical pulse.
Instead of using wires that can get infected and dislodged, we can implant this leadless biocompatible pacemaker, Arora said. The circuitry is implanted directly on the surface of the heart, and we can activate it remotely. Over a period of weeks, this new type of pacemaker dissolves or degrades on its own, thereby avoiding the need for physical removal of the pacemaker electrodes. This is potentially a major victory for post-operative patients.
With further modifications, it eventually may be possible to implant such bioresorbable pacemakers through a vein in the leg or arm, he added. In this instance, it also may be possible to provide temporary pacing to patients who have suffered a heart attack or to patients undergoing catheter-based procedures, such as transcatheter aortic valve replacement.
Northwestern Medicine cardiac surgeon Dr. Duc Thinh Pham, who was not involved with the research, imagines a transient pacemaker undoubtedly would make his patients more comfortable. With current pacemakers, patients often feel discomfort for days after the leads are inserted. Then, they must limit their movements and activities to prevent the leads from dislodging.
This transient pacemaker is brilliant, said Pham, who has performed more than 2,000 cardiac surgeries throughout his career. In addition to addressing the primary issue of occasional post-cardiac surgery patients needing temporary pacing due to blockages or arrhythmias, the device addresses the secondary issue of patient comfort, ability to move freely and rehabilitate. If successful, this device will greatly improve a patients postoperative course.
This is the second example of bioresorbable electronic medicine from the Rogers lab, which has been studying transient electronics for over a decade. In 2018, Rogers and colleagues demonstrated the worlds first bioresorbable electronic device a biodegradable implant that speeds nerve regeneration. The teams bioresorbable devices are completely harmless similar to absorbable stitches. After fully degrading, the devices completely disappear through the bodys natural biological processes.
There is clearly a need for better temporary cardiac pacemakers, said Dr. Bradley Knight, the Chester C. and Deborah M. Cooley Distinguished Professor of Cardiology at Feinberg and coauthor of the study. When I first learned about the bioresorbable nerve stimulator, I contacted Professor Rogers to explore the possibility of using this technology to pace the heart. He had already started working with Dr. Efimov to develop a small version of a bioresorbable pacemaker as a proof of concept. We then worked with both teams to develop a larger version of a bioresorbable, leadless cardiac pacemaker that could be effective on a human scale. Its a great example of what we can create at Northwestern by bridging the expertise in engineering and medicine.
A temporary pacemaker might be needed anywhere from a couple of days to several weeks, depending on the patient. By varying the composition and thickness of the materials in the device, Rogers team can control the precise number of days it remains functional before dissolving.
We build these devices out of different types of safe, bioresorbable materials and in optimized architectures to ensure stable operation over a time period somewhat longer than is clinically necessary, Rogers said. We can tailor the devices to address a broad spectrum of relevant lifetimes. Transient technologies, in general, could someday provide therapy or treatment for a wide variety of medical conditions serving, in a sense, as an engineering form of medicine.
Read more from the original source:
This Is The Worlds First-Ever Transient Pacemaker That Can Harmlessly Dissolve In The Body - Wonderful Engineering
- Cardiac Regeneration - Center for Regenerative Medicine - Mayo Clinic ... - April 11th, 2018 [April 11th, 2018]
- Cardiac Regeneration - Mayo Clinic - April 22nd, 2018 [April 22nd, 2018]
- Materials - MDPI - May 18th, 2018 [May 18th, 2018]
- Cardiac Stem Cell Research - Cedars-Sinai - May 22nd, 2018 [May 22nd, 2018]
- Cardiac regeneration: current therapiesfuture concepts ... - May 26th, 2018 [May 26th, 2018]
- Cardiac Regeneration - Victor Chang Cardiac Research Institute - May 30th, 2018 [May 30th, 2018]
- Cardiology Conferences | Cardio 2018 Events | Cardiac ... - June 6th, 2018 [June 6th, 2018]
- Laboratory for Cardiac Regeneration | Baylor College of ... - June 18th, 2018 [June 18th, 2018]
- Regeneration of Muscle - July 8th, 2018 [July 8th, 2018]
- Regeneration of Muscle - eLS: Essential for Life Science - July 14th, 2018 [July 14th, 2018]
- Cardiac Repair and Regeneration Research Unit | Heart and ... - July 25th, 2018 [July 25th, 2018]
- Myogenesis - Wikipedia - August 8th, 2018 [August 8th, 2018]
- Regeneration (biology) - Wikipedia - August 21st, 2018 [August 21st, 2018]
- World Cardiology and Cardiologist Meeting - August 21st, 2018 [August 21st, 2018]
- Cardiac (comics) - Wikipedia - August 26th, 2018 [August 26th, 2018]
- Cardiac regeneration and repair - 1st Edition - Elsevier - September 21st, 2018 [September 21st, 2018]
- Post-doc position available cardiac regeneration ... - September 29th, 2018 [September 29th, 2018]
- UW Bioengineering: Building World Leadership in Heart ... - September 29th, 2018 [September 29th, 2018]
- Cardiac Regeneration - What Science Can Do - AstraZeneca - October 2nd, 2018 [October 2nd, 2018]
- Cardiac Regeneration, Stem Cells | Research | Baylor ... - November 30th, 2018 [November 30th, 2018]
- Cardiac Regeneration - Victor Chang Institute - December 6th, 2018 [December 6th, 2018]
- Entering a new era in vascular and cardiac regeneration ... - December 19th, 2018 [December 19th, 2018]
- Cardiac regeneration and repair - 1st Edition - December 19th, 2018 [December 19th, 2018]
- Heart Regeneration Technologies - December 19th, 2018 [December 19th, 2018]
- Cardiac Regeneration - Center for Regenerative Medicine ... - December 19th, 2018 [December 19th, 2018]
- Zebrafish Heart Regeneration | HHMI BioInteractive - December 22nd, 2018 [December 22nd, 2018]
- Rapid cell regeneration - Heroes Wiki - December 22nd, 2018 [December 22nd, 2018]
- Cardiac muscle - Wikipedia - December 23rd, 2018 [December 23rd, 2018]
- Cardiac regeneration in and : discrepancies and problems ... - January 8th, 2019 [January 8th, 2019]
- OHSU Center for Regenerative Medicine Heart Regeneration ... - January 8th, 2019 [January 8th, 2019]
- Dr. Sanjiv Dhingra, Cardiac Regeneration and Tissue ... - January 30th, 2019 [January 30th, 2019]
- Mending a Broken Heart: Stem Cells and Cardiac Repair ... - February 20th, 2019 [February 20th, 2019]
- Cardiac Repair and Regeneration | Division of Cardiology ... - February 20th, 2019 [February 20th, 2019]
- Stem Cell Therapy and Stem Cell Injection Provider Finder ... - March 5th, 2019 [March 5th, 2019]
- KearnsSayre syndrome - Wikipedia - March 8th, 2019 [March 8th, 2019]
- Ruohola-Baker Lab - March 15th, 2019 [March 15th, 2019]
- MTS Science - May 3rd, 2019 [May 3rd, 2019]
- New Insights Into the Healing Capacity of the Heart: The Hippo Pathway - Cath Lab Digest - September 26th, 2019 [September 26th, 2019]
- Conjugated polymers optically regulate the fate of endothelial colony-forming cells - Science Advances - September 29th, 2019 [September 29th, 2019]
- The nanoengineer working to mend broken hearts - UNSW Newsroom - September 29th, 2019 [September 29th, 2019]
- New insights into heart's healing capacity - Baylor College of Medicine News - September 29th, 2019 [September 29th, 2019]
- Tenaya Therapeutics Closes $92 Million Series B Financing - BioSpace - October 5th, 2019 [October 5th, 2019]
- Regenerative medicine today: Are diabetes and vascular disease treatments ready for the clinic? - Science Magazine - October 5th, 2019 [October 5th, 2019]
- Reviewing resTORbio Inc. (TORC)'s and Anika Therapeutics Inc. (NASDAQ:ANIK)'s results - MS Wkly - October 14th, 2019 [October 14th, 2019]
- TAMassociati: the new Church of the Resurrection in Varignano - Floornature.com - October 14th, 2019 [October 14th, 2019]
- What the Hippo pathway in cardiac fibroblasts reveals about heart function - Baylor College of Medicine News - October 19th, 2019 [October 19th, 2019]
- Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD) - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities - Health News Office - October 24th, 2019 [October 24th, 2019]
- Ottawa-based treatment a leap forward in addressing heart failure - Winnipeg Sun - October 27th, 2019 [October 27th, 2019]
- Global Regenerative Medicines Market Demand Analysis & Opportunity Evaluation Report 2019-2027 with Focus on U.S. & Europe -... - November 15th, 2019 [November 15th, 2019]
- The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure - Physician's Weekly - November 15th, 2019 [November 15th, 2019]
- SANUWAVE Health Reports Third Quarter 2019 Financial Results Other OTC:SNWV - GlobeNewswire - November 16th, 2019 [November 16th, 2019]
- Moderna: Undervalued As The Promising Pipeline Awaits Collaborations - Seeking Alpha - November 23rd, 2019 [November 23rd, 2019]
- Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction... - November 23rd, 2019 [November 23rd, 2019]
- Stem Cell Therapy May Improve Heart Health In New Ways - TheHealthMania - December 5th, 2019 [December 5th, 2019]
- AgeX Therapeutics Issues Year-End Letter to Shareholders - BioSpace - December 9th, 2019 [December 9th, 2019]
- Polymeric Biomaterials Market Trends Analysis Forecast to 2019-2024 |Evolving Industry Overview by Types, Applications, Size & Share - Sino News... - December 16th, 2019 [December 16th, 2019]
- SMD - Researchers look behind the biological curtain on how fish oil might fight inflammatory disease - QMUL - December 16th, 2019 [December 16th, 2019]
- Suspended animation, you say? The biggest and freakiest scientific breakthroughs of 2019 - SYFY WIRE - December 29th, 2019 [December 29th, 2019]
- 2019: Year in Pictures by Robert Cohen | Metro - STLtoday.com - December 31st, 2019 [December 31st, 2019]
- MicroCures Announces Issuance of New Patent Covering First-of-its-Kind Cell Movement Decelerator Technology with Potential Applications in Oncology... - January 15th, 2020 [January 15th, 2020]
- Cells that regenerate heart in zebrafish discovered - Biology Reporter - February 7th, 2020 [February 7th, 2020]
- SANUWAVE Health Appoints Dr. Tom Price to Its Board of Directors - Yahoo Finance - February 7th, 2020 [February 7th, 2020]
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - Associated Press - March 19th, 2020 [March 19th, 2020]
- Researchers and Doctors alike pursuing the field of stem cell research in treating heart attack survivors - Medical Herald - March 19th, 2020 [March 19th, 2020]
- Artificial Heart Lung Machines Market report reviews opportunities and analysis by size, share, trends, manufacturer, forecast 2020-2026 - WhaTech... - April 29th, 2020 [April 29th, 2020]
- Scientists have figured out how to make the heart to regenerate - The Times Hub - April 29th, 2020 [April 29th, 2020]
- Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat dietinduced obesity - Science Advances - May 9th, 2020 [May 9th, 2020]
- SANUWAVE HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - May 15th, 2020 [May 15th, 2020]
- SANUWAVE Health to Hold First Quarter Financial Results and Business Update Call on Monday, May 18, 2020 - Yahoo Finance - May 15th, 2020 [May 15th, 2020]
- SANUWAVE Health to Hold Investor Live Webcast on Wednesday, June 10, 2020 - Yahoo Finance - June 10th, 2020 [June 10th, 2020]
- SANUWAVE Health Enters Into Exclusive Letter of Intent to Acquire Celularity's UltraMIST and Exclusive Partnership Rights for Wound Care Biologic... - June 11th, 2020 [June 11th, 2020]
- SANUWAVE Health, Inc. Discusses The Potential of Their Celularity Acquisition with The Stock Day Podcast (SNWV) July 1, 2020 - Stock Day Media - July 1st, 2020 [July 1st, 2020]
- Interim Analysis of Recardio's Phase II Clinical Trial to Be Presented at the 2020 Congress of the European Society of Cardiology - PRNewswire - July 1st, 2020 [July 1st, 2020]
- Growth and demand of Plasma Therapy in the Asia Pacific Region available in the latest report - WhaTech Technology and Markets News - July 4th, 2020 [July 4th, 2020]
- Plasma Therapy Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line - August 14th, 2020 [August 14th, 2020]
- Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Publication on the Use of Excellagen for Vascular Repair - BioSpace - August 14th, 2020 [August 14th, 2020]
- Polymeric Biomaterials Market Insights by Current Trends 2020 Future Demand by Top Key Players, Regions, Industry Size, and Business Strategy... - September 11th, 2020 [September 11th, 2020]
- CORRECTION - SANUWAVE Health Announces Reimbursement Coverage for BIOVANCE From Largest Medicare and Medicaid Administrator in U.S. - Stockhouse - September 11th, 2020 [September 11th, 2020]
- New Research Paper Suggests RegeneRx's Thymosin Beta 4 May be Useful in Treating COVID-19 - PRNewswire - September 11th, 2020 [September 11th, 2020]